# A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time

> **NCT07839884** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 1360 (estimated)

## Conditions studied

- Moderate to Severe Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Tilrekimig

## Key facts

- **NCT ID:** NCT07839884
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-21
- **Primary completion:** 2034-05-12
- **Final completion:** 2034-05-12
- **Target enrollment:** 1360 (ESTIMATED)
- **Last updated:** 2026-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07839884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07839884, "A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07839884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
